Risultati della ricerca - Albert Oriol

Raffina i risultati
  1. 1
    Acute Lymphoblastic Leukemia in Adolescents and Young Adults

    Acute Lymphoblastic Leukemia in Adolescents and Young Adults di Josep‐María Ribera, Albert Oriol

    Pubblicazione 2009
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Influence of highly active anti‐retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome‐related non‐Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone

    Influence of highly active anti‐retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome‐related non‐Hodgkin's lymphoma treated... di José‐Tomás Navarro, Josep‐María Ribera, Albert Oriol, M Vaquero, Joan Romeu, Montserrat Batlle, Alonso Flores, Fuensanta Millá, Evarist Feliú

    Pubblicazione 2001
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in Pediatrics

    Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in Pediatrics di Hansa Bhargava, Carmela Salomon, Srinivasan Suresh, Anthony Chang, Rachel Kilian, Diana van Stijn, Albert Oriol, Daniel Low, Ashley Knebel, Sharief Taraman

    Pubblicazione 2024
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial

    Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: r... di Josep‐María Ribera, Albert Oriol, Mireia Morgades, Eva González‐Barca, Pilar Miralles, Armando López‐Guillermo, Santiago Gardella, Andrés López, Eugènia Abella, Marta García

    Pubblicazione 2007
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Bone Marrow Changes in Anorexia Nervosa Are Correlated With the Amount of Weight Loss and Not With Other Clinical Findings

    Bone Marrow Changes in Anorexia Nervosa Are Correlated With the Amount of Weight Loss and Not With Other Clinical Findings di Eugènia Abella, Evarist Feliú, Isabel Granada, Fuensanta Millá, Albert Oriol, Josep‐María Ribera, Luis Sánchez-Planell, Ll. Berga, Joan Carles Reverter, C Rozmán

    Pubblicazione 2002
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

    Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups di Robert Z. Orlowski, Philippe Moreau, Rubén Niesvizky, Heinz Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy Kimball, Meletios Α. Dimopoulos

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma

    High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma di Albert Oriol, Josep‐María Ribera, Juan Bergua, Eduardo Giménez Mesa, Carlos Grande, Jordi Esteve, Salut Brunet, María‐José Moreno, Lourdes Escoda, Jesús María Hernández‐Rivas, Dieter Hoelzer

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

    Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment di Marcelo Capra, Thomas G. Martin, Philippe Moreau, Gracia Martínez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea M. Rawlings, Christina Tekle, Sandrine Macé, Marie‐Laure Risse, Ivan Špıčka

    Pubblicazione 2022
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

    A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis di María Teresa Cibeira, Albert Oriol, Juan José Lahuerta, María‐Victoria Mateos, Javier de la Rubia, Miguel‐Teodoro Hernández, Miquel Granell, Carlos Fernández de Larrea, Jesús F. San Miguel, Joan Bladé

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma

    Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma di María‐Victoria Mateos, Miguel Granell, Albert Oriol, Joaquín Martínez‐López, Joan Bladé, Miguel‐Teodoro Hernández, Jesús Martín, Mercedes Gironella, Mark Lynch, Eric Bleickardt, Prashni Paliwal, Anil Singhal, Jesús F. San Miguel

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM</scp> Trial

    Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIM... di Paul G. Richardson, Meral Beksaç, Albert Oriol, Jindriska Lindsay, Fredrik Schjesvold, Mónica Galli, Münci Yağcı, Alessandra Larocca, Katja Weisel, Xin Yu, Cynthia Donahue, Jorge Acosta‐Reyes, Teresa Peluso, Meletios Α. Dimopoulos

    Pubblicazione 2025
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.

    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. di Thierry Façon, Philippe Moreau, Thomas G. Martin, Ivan Špıčka, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, Sandrine Schwab, Gracia Martínez

    Pubblicazione 2021
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis

    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis di Thierry Façon, Philippe Moreau, Thomas G. Martin, Ivan Špıčka, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, Sandrine Schwab, Gracia Martínez

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

    The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma di Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Façon, Ivan Špıčka, Albert Oriol, Kenshi Suzuki, Edvan de Queiroz Crusoé, Ajai Chari, Nicole M. Armstrong, Christina Tekle, Marie‐Laure Risse, Thomas G. Martin, Philippe Moreau

    Pubblicazione 2023
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study

    Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study di Manuela Aguilar‐Guisado, Margarita Jiménez‐Jambrina, Ildefonso Espigado, Montserrat Rovira, Rodrigo Martino, Albert Oriol, Núria Borrell, Isabel Ruiz‐Camps, Pilar Martín‐Dávila, Rafael de la Cámara, M Salavert, Julián de la Torre, José Miguel Cisneros

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Automated prioritization of sick newborns for whole genome sequencing using clinical natural language processing and machine learning

    Automated prioritization of sick newborns for whole genome sequencing using clinical natural language processing and machine learning di Bennet Peterson, Edgar J. Hernández, Charlotte A. Hobbs, Sabrina Malone Jenkins, Barry Moore, Edwin F. Juarez, Samuel Zoucha, Erica Sanford Kobayashi, Matthew N. Bainbridge, Erwin Frise, Albert Oriol, Luca Brunelli, Stephen F. Kingsmore, Mark Yandell

    Pubblicazione 2023
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    A new prognostic score for AIDS-related lymphomas in the rituximab-era

    A new prognostic score for AIDS-related lymphomas in the rituximab-era di Stefan K. Barta, Xiaonan Xue, De‐Shen Wang, J. Y. Lee, Lawrence D. Kaplan, Josep‐María Ribera, Albert Oriol, Michele Spina, Umberto Tirelli, François Boué, Wyndham H. Wilson, Christoph Wyen, Kieron Dunleavy, Ariela Noy, Joseph A. Sparano

    Pubblicazione 2014
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  18. 18
    Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

    Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final re... di Josep‐María Ribera, Albert Oriol, Marcos González, María‐Belén Vidriales, S. Brunet, Jordi Esteve, Eloy del Potro, C Rivas, M.-J. Moreno, Mar Tormo, Victoria Martín-Reina, Josep Sarrà, Ricardo Parody, Jaime Pérez de Oteyza, E Bureo, Teresa Bernal

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

    Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-do... di María‐Victoria Mateos, Sara Bringhen, PG Richardson, Juan José Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García‐Sánz, Francesco Di Raimondo, Dixie Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

    Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. di Ivan Špıčka, Philippe Moreau, Thomas G. Martin, Thierry Façon, Gracia Martínez, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi van de Velde, Kwee Yong

    Pubblicazione 2021
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: